Although the two diseases are completely different, nobody can predict when or if COVID-19 will disappear just like in the case of HIV, he added. "Solidarity within and between countries and the private sector is essential if we are to overcome these hard times".
Hill said that as of this week, more than 1,000 people have been dosed in the trial - with around half getting the experimental vaccine and the other half serving as a control group. Experts have suggested that a COVID-19 vaccine could take 12-18 months to develop. But he warned that there are no certainties and it is possible trials may not lead to a successful coronavirus vaccine.
China has reported 17 new coronavirus cases, including 12 asymptomatic infections, while officials in Wuhan, where the outbreak originated, continued vigorous testing of its over 11 million residents after new clusters of COVID-19 emerged in parts of the city.
The Oxford University has confirmed a global licensing agreement with AstraZeneca , which will make 30 million vaccine doses available to Britain by September if the trials are successful, as part of an agreement for 100 million doses in total, said the secretary.
Anyhow, it is an immunity system similar to humans that exists in these Rhesus Macaques monkeys on which this vaccine was tested. An experimental vaccine developed by researchers at Oxford University has shown promise in preventing COVID-19, according to a small trial in six monkeys.
To expand its access, Gilead said this week it had signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan, allowing them to make and sell remdesivir for 127 countries. Remdesivir is the only drug approved to treat COVID-19 patients. Roche licensed Hyderabad-based Hetero to make and sell it in the local Indian and other developing markets.